Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.35 USD | -0.89% | -2.79% | -16.63% |
Apr. 19 | BMO Capital Adjusts Price Target on Incyte to $56 From $64 | MT |
Apr. 01 | Incyte, China Medical System Sign Collaboration, License Agreement | MT |
Evolution of the average Target Price on Incyte Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Incyte Corporation
BMO Capital | |
Jefferies & Co. | |
Citigroup | |
JMP Securities | |
Truist Securities | |
Stifel Nicolaus | |
RBC Capital Markets | |
Mizuho Securities | |
SVB Securities LLC | |
Guggenheim | |
Goldman Sachs | |
Morgan Stanley | |
BofA Securities | |
Morningstar | |
TD Cowen | |
Oppenheimer | |
Cowen | |
Evercore ISI | |
Piper Sandler | |
Wells Fargo Securities | |
JPMorgan Chase | |
SVB Leerink | |
Benchmark Capital | |
Credit Suisse |
EPS Revisions
- Stock Market
- Equities
- INCY Stock
- Consensus Incyte Corporation